APM (APM) Stock Price & Analysis
APM (APM) fell 4.27% to USD 1.12 as of June 10, 2026 at 02:14 UTC, according to Nexqual real-time market data.
APM last closed at USD 1.17; the session ranged USD 1.01–1.21 on volume of 773,871 shares. Market capitalization is $9.12M, with a 52-week range of USD 0.65–4.47 (NCM). Source: Nexqual, June 10, 2026 at 02:14 UTC.
Key Statistics (as of June 10, 2026 at 02:14 UTC)
| Price | USD 1.12 |
|---|---|
| Change | ▼ 4.27% (down) |
| Previous Close | USD 1.17 |
| Open | USD 1.16 |
| Day Range | USD 1.01 – 1.21 |
| 52-Week Range | USD 0.65 – 4.47 |
| Volume | 773,871 shares |
| Market Cap | $9.12M |
| Exchange | NCM |
Technical Analysis (APM)
Nexqual's technical model rates APM "STRONG BUY" based on 5 bullish and 0 bearish signals across 124 daily candles, as of June 10, 2026 at 02:14 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 62.62 (neutral) |
| vs SMA50 | Above (USD 0.9) |
| MACD | 0.06 (positive) |
Analyst Ratings (APM)
Wall Street analysts rate APM "None", per Nexqual as of June 10, 2026 at 02:14 UTC.
| Consensus Rating | None |
|---|
Earnings (APM)
Source: Nexqual, June 10, 2026 at 02:14 UTC.
Financials & Fundamentals (APM)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -10.79% |
| Debt / Equity | 25.05 |
| Current Ratio | 0.78 |
| Total Cash | $3.45M |
| Total Debt | $3.44M |
| Free Cash Flow | $-1.10M |
Source: Nexqual, June 10, 2026 at 02:14 UTC.
Financial Health Score (APM)
Nexqual rates APM's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:14 UTC.
| Growth | Critical — Revenue -16% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Solid — $3M cash vs $3M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$1M, burning cash |
| Efficiency | Critical — ROE -11%, ROA -6.5% |
Ownership (APM)
| Insider Ownership | +16.41% |
|---|---|
| Institutional Ownership | +2.47% |
| Shares Outstanding | 6.35M |
| Float | 5.36M |
| Short % of Float | +0.04% |
Source: Nexqual, June 10, 2026 at 02:14 UTC.
Leadership (APM)
APM is led by Chung Yuen Huen (age 45), Founder, CEO & Executive Director, per Nexqual as of June 10, 2026 at 02:14 UTC.
| Founder, CEO & Executive Director | Chung Yuen Huen (age 45) |
|---|
Major Backers & Investors (APM)
Notable institutional backers of APM include Citadel, Fidelity, Susquehanna International Group, LLP, according to Nexqual as of June 10, 2026 at 02:14 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Citadel | 1.46% |
| Fidelity | 1.13% |
| Susquehanna International Group, LLP | 0.26% |
| Xtx Topco Ltd | 0.24% |
| Morgan Stanley | 0.21% |
| Renaissance Technologies | 0.19% |
Source: Nexqual, June 10, 2026 at 02:14 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ADIL | Adial Pharmaceuticals, Inc | USD 2.13 | ▼ 3.62% |
| LIXT | Lixte Biotechnology Holdings, I | USD 6.87 | ▼ 1.86% |
| ATHE | Alterity Therapeutics Limited | USD 4.29 | ▲ 10% |
| ADTX | Aditxt, Inc. | USD 0.03 | ▼ 53.39% |
| PHIO | Phio Pharmaceuticals Corp. | USD 1.08 | ▲ 1.89% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:14 UTC. This page is informational and not investment advice.